Bayer AG Return on Assets (ROA) Growth & History (BAYN)
Bayer AG's return on assets (roa) was −3.34% for fiscal 2025.
View full Bayer AG company overviewBayer AG annual return on assets (roa) history
| Fiscal year | Period ended | Return on assets (ROA) | Change (percentage points) |
|---|---|---|---|
| 2025 | 2025-12-31 | −3.34% | −1.10 pp |
| 2024 | 2024-12-31 | −2.24% | +0.20 pp |
| 2023 | 2023-12-31 | −2.44% | −5.84 pp |
| 2022 | 2022-12-31 | 3.40% | +2.54 pp |
| 2021 | 2021-12-31 | 0.86% | +9.48 pp |
| 2020 | 2020-12-31 | −8.62% | −11.88 pp |
| 2019 | 2019-12-31 | 3.25% | +1.56 pp |
| 2018 | 2018-12-31 | 1.70% | −8.59 pp |
| 2017 | 2017-12-31 | 10.29% | +4.11 pp |
| 2016 | 2016-12-31 | 6.18% | +0.50 pp |
| 2015 | 2015-12-31 | 5.69% | +0.02 pp |
| 2014 | 2014-12-31 | 5.67% | −0.54 pp |
| 2013 | 2013-12-31 | 6.21% | +1.41 pp |
| 2012 | 2012-12-31 | 4.80% | +0.05 pp |
| 2011 | 2011-12-31 | 4.74% | — |
Bayer AG quarterly return on assets (roa)
| Fiscal quarter | Period ended | Return on assets (ROA) | Change (percentage points) |
|---|---|---|---|
| Q2 2026 | 2026-06-30 | 0.20% | — |
| Q1 2026 | 2026-03-31 | 2.60% | — |
| Q4 2025 | 2025-12-31 | −3.60% | — |
| Q3 2025 | 2025-09-30 | −0.92% | — |
Bayer AG return on assets (roa) trends
Over the last five fiscal years, Bayer AG's return on assets (roa) increased from −8.62% to −3.34%, a change of +5.28 percentage points. The latest reported quarter, Q2 2026, shows 0.20%.
What return on assets means
Return on assets measures profit relative to the assets used to generate it. It can help compare operating efficiency over time, although normal ROA differs substantially between asset-light and asset-intensive industries.
How return on assets is calculated
TickerStat calculates annual ROA as reported net income divided by average total assets. Quarterly observations use trailing-12-month net income and average assets over the corresponding one-year period. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Bayer AG source filings ↗Community posts
Bayer wins the first Roundup trial following the Supreme Court ruling
A Missouri jury unanimously ruled for Bayer ($BAYN)’s Monsanto unit in a three-plaintiff Roundup case, rejecting design-defect, fraud and negligence claims. It was the first such trial following the US Supreme Court decision that blocked th ...
Bayer’s Nubeqa cuts risk of metastasis or death in prostate trial
Bayer ($BAYN) disclosed interim Phase 3 results showing that adding Nubeqa to hormone therapy and radiation reduced the risk of metastasis or death by 58% in prostate-cancer patients at high risk of recurrence. Four-year metastasis-free sur ...